Other mutations (such as non-T790M EGFR mutations D761Y, L747S and T854A, amplification of c-Met, loss of PTEN, PIK3CA mutations and BIM BH3 deletion) have been reported to result in the resistance to EGFR TKIs in some cancers [42]. Here, BCL2L11 is linked to cancer.